


# Digital biomarkers and health measurement in clinical trials

Anzar Abbas, PhD

## Disclosures

- Employee, hold stock in Brooklyn Health
- Former employee, hold stock in AiCure

# Digital health measurement



## Operational challenges with deployment



**Study participants**  
Burdensome platforms; value unclear




**Clinical sites**  
Operational complexity; lack of support




**Study sponsors**  
Questionable return on investment

## Need for trust, standardization, and interoperability




### Trust in methods

Accessible methods and open code



### Standardization

Same measures regardless of context



### Interoperability


Measures that are platform agnostic

## Some use cases remain unexplored



### Screening, enrichment

Use of measures to find/select the right patients



### Digital endpoints

Utilize measures regardless of context



### Measurement-based care

Use evidence generated post-approval